Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12–49

Article  PubMed  Google Scholar 

O’Sullivan CC, Clarke R, Goetz MP, Robertson J (2023) Cyclin-dependent kinase 4/6 inhibitors for treatment of hormone receptor–positive, ERBB2-negative breast cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.2000

Schettini F, Martínez-Sáez O, Falato C, De Santo I, Conte B, Garcia-Fructuoso I, Gomez-Bravo R, Seguí E, Chic N, Brasó-Maristany F et al (2023) Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis. ESMO Open 8(3). https://doi.org/10.1016/j.esmoop.2023.101214

Huppert LA, Gumusay O, Idossa D, Rugo HS (2023) Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin 73(5):480–515

Article  PubMed  Google Scholar 

Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M et al (2016) Endocrine therapy for hormone receptor–positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 34(25):3069–3103

Article  CAS  PubMed  Google Scholar 

Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M (2024) Recent progress of CDK4/6 inhibitors’ current practice in breast cancer. Cancer Gene Ther. https://doi.org/10.1038/s41417-024-00747-x

Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V et al (2016) Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell 29(3):255–269

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Sullivan CC, Suman VJ, Goetz MP (2019) The emerging role of CDK4/6i in HER2-positive breast cancer. Ther Adv Med Oncol 11. https://doi.org/10.1177/1758835919887665

Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. The Lancet 395(10226):817–827

Article  CAS  Google Scholar 

Zhao M, Hanson KA, Zhang Y, Zhou A, Cha-Silva AS (2023) Place in therapy of cyclin-dependent kinase 4/6 inhibitors in breast cancer: a targeted literature review. Target Oncol 18(3):327–358

Article  PubMed  PubMed Central  Google Scholar 

Fuentes‐Antrás J, Bedard PL, Cescon DW (2024) Seize the engine: emerging cell cycle targets in breast cancer. Clin Transl Med 14:e1544. https://doi.org/10.1002/ctm2.1544

Spring LM, Zangardi ML, Moy B, Bardia A (2017) Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist 22(9):1039–1048

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wekking D, Leoni VP, Lambertini M, Dessì M, Pretta A, Cadoni A, Atzori L, Scartozzi M, Solinas C (2024) CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: biological and clinical aspects. Cytokine Growth Factor Rev 75:57–64. https://doi.org/10.1016/j.cytogfr.2023.10.001

Article  CAS  PubMed  Google Scholar 

Gao JJ, Cheng J, Prowell TM, Bloomquist E, Tang S, Wedam SB, Royce M, Krol D, Osgood C, Ison G et al (2021) Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. Lancet Oncol 22(11):1573–1581

Article  CAS  PubMed  Google Scholar 

Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936

Article  CAS  PubMed  Google Scholar 

Tripathy D, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS et al (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904–915

Article  CAS  PubMed  Google Scholar 

Johnston SRD, Harbeck N, Martin M, Shao ZM, Campone M, Wei R, Hamilton E, Hegg R, Zhang QY, Rodriquez JLM, Sohn J, Guarneri V, Tolaney SM, MPH19, Cicin I, Smith IC, Antonio BS, Hulstijn M, Okada M, FB, Neven P, Cortés J, Wardley A, Headley D, O’Shaughnessy J, Rastogi P, J C, Frenzel M, (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 38:3987–3998. https://doi.org/10.1200/JCO.20.02514

Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, Sun T, Teng Y, Wu X, Ouyang Q et al (2021) Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med 27(11):1904–1909. https://doi.org/10.1038/s41591-021-01562-9

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W et al (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386(10):942–950

Article  CAS  PubMed  Google Scholar 

Thill M, Schmidt M (2018) Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 10:1–12. https://doi.org/10.1177/1758835918793326

Article  CAS  Google Scholar 

Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M (2021) Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist 26(1):e53–e65

Article  CAS  PubMed  Google Scholar 

Desnoyers A, Nadler MB, Kumar V, Saleh R, Amir E (2020) Comparison of treatment-related adverse events of different cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: a network meta-analysis. Cancer Treat Rev 90:102086. https://doi.org/10.1016/j.ctrv.2020.102086

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71

Higgins JP, Savović J, Page MJ, Elbers RG Sterne JA (2023) Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,Welch VA (eds) Cochrane handbook for systematic reviews of interventions. Cochrane. Available from http://www.training.cochrane.org/handbook

Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–60

Article  PubMed  PubMed Central  Google Scholar 

Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, Hu X, Cheng Y, Yan M, Pan Y et al (2023) Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 24(6):646–657

Article  CAS  PubMed  Google Scholar 

Neven P, Fasching PA, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Martín M, Nusch A et al (2023) Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res 25:103. https://doi.org/10.1186/s13058-023-01701-9

Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, Ahn H, Trivedi MS, Novik Y, Tiersten A et al (2023) Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: MAINTAIN Trial. J Clin Oncol 41(24):4004–4013

Article  CAS  PubMed  Google Scholar 

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35

Article  CAS  PubMed  Google Scholar 

Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im S-A, Masuda N, Loi S, André F, Harbeck N et al (2017) Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 Results. Oncologist 22(9):1028–1038

Article  CAS  PubMed  PubMed Central  Google Scholar 

Albanell J, Martínez MT, Ramos M, O’Connor M, de la Cruz-Merino L, Santaballa A, Martínez-Jañez N, Moreno F, Fernández I, Alarcón J et al (2022) Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER). Eur J Cancer 161:26–37

Article  CAS  PubMed  Google Scholar 

Loibl S, Marmé F, Kim SB, Bear H, McCarthy N, Olivé MM, García-Sáenz J, Denkert C, Huang-Bartelett C, Burchardi N, Kelly CM, Nekljudova V, Reimer T, Gnant M, Frean MJL, Makris A, Colleoni M, Martin M, Untch M, Bonnefoi H, Gelmon K, Rugo HS, Toi M, M K, Werutsky G, von Minckwitz G, (2021) Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the penelope-B trial. J Clin Oncol 39:1518–1530. https://doi.org/10.1200/JCO.20.03639

Article  CAS  PubMed  Google Scholar 

Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35:2875–2884. https://doi.org/10.1200/JCO.2017.73.7585

Article  CAS  PubMed  Google Scholar 

Stanciu I-M, Parosanu AI, Nitipir C (2023) An overview of the safety profile and clinical impact of CDK4/6 inhibitors in breast cancer—a systematic review of randomized phase II and III clinical trials. Biomolecules 13(9)

Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E et al (2019) Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+/HER2- advanced breast cancer. J Natl Cancer Inst 111(4):419–430. https://doi.org/10.1093/jnci/djy109

Article